maximizing the role of adcs in urothelial carcinoma
Published 11 days ago • 99 plays • Length 1:31:33Download video MP4
Download video MP3
Similar videos
-
40:12
improving patient outcomes in urothelial carcinoma with novel antibody–drug conjugates
-
31:39
the evolving role of antibody-drug conjugates in the treatment of urothelial carcinoma
-
0:58
adcs in the management of urothelial carcinoma
-
0:55
adcs for advanced urothelial carcinoma
-
2:30
the future of antibody-drug conjugates in urothelial cancer
-
0:54
where do adcs fit in the treatment landscape of urothelial carcinoma?
-
1:32
antibody-drug conjugates in urothelial carcinoma
-
3:06
how effective are adcs in treating metastatic urothelial cancer?
-
1:21:32
antibody–drug conjugates for solid tumors: progress, possibilities, and implications for care
-
1:10:42
revolutionizing solid tumor treatment: unleashing the potential of antibody-drug conjugates
-
1:58
what’s next for antibody drug conjugates in urothelial carcinoma?
-
1:26:20
expert panel discussion on the latest evidence and treatment advancements in bladder cancer care
-
0:46
sequencing adcs and finding novel biomarkers for urothelial carcinoma
-
1:44
adcs in the treatment landscape of patients with advanced uc
-
0:38
novel combined adcs in metastatic urothelial carcinoma: insights from esmo 2023
-
0:33
adcs for advanced uc and their molecular markers of response
-
48:40
taking aim with the next wave of antibody–drug conjugates in nsclc to address unmet needs
-
57:16
antibody-drug conjugates in the clinic: